Lonza announces the launch of its new innovative MuscleGuard formulation, a unique patent-pending ingredient combination comprising a precise and clinically-studied ratio of four nutrients - Lonza's CarnipureL-Carnitine, Creatine and Leucine with vitamin D.
The science-backed vegan MuscleGuard formulation delivers positive results for sports performance and recovery through statistically significant increases in muscle strength, mass and activity. Lonza will be introducing MuscleGuard formulation to the United States market today at SupplySide West (booth 4339).
The MuscleGuard Effect
Lonza's new MuscleGuard formulation comprises a unique blend of four ingredients - Carnipure L-Carnitine, creatine and leucine with vitamin D. It was found to deliver significant muscle health benefits, including a 63% increase in muscle strength, mass and activity in a clinical study on older people to support consumers' sports and exercise aspirations.
Lonza's patent-pending MuscleGuard formulation is ideal for use by both male and female athletes and active individuals. Vegan and vegetarian, it offers nutritional support for pre-, intra- and post-workout. Convenient as a standalone sports drink mix, it can also be easily incorporated into existing sports nutrition regimes such as protein powders and shakes. This innovative patent pending formulation combines new scientifically supported results, smaller dosing and addresses demand for vegans and vegetarians.
Shane Durkee, Vice President of Platform Innovation Consumer Health and Nutrition at Lonza, comments: 'At Lonza, we continue to push the boundaries of science-backed technologies to help brands create cleaner, healthier and more effective products that active consumers' demand. Our new vegan MuscleGuard solution showcases our science-led approach to ingredient innovation - bringing clinical evidence together with consumer trends and preferences.'
'A randomized, double-blind, placebo-controlled clinical trial on healthy older participants for eight weeks showed a composite score of muscle mass, strength and physical activity that was statistically significant in MuscleGuard supplementation compared to the placebo2. In addition, individuals who received the MuscleGuard formulation also displayed a 1.0 kg increase in total lean muscle mass, leg lean muscle mass, and a 1.0 kg increase in lower leg strength, without diet or exercise modification,' comments Dr. Aouatef Bellamine, Senior Scientific Manager, Lonza Consumer Health & Nutrition, who lead the clinical study.
Further investigation into the innovative formulation's mechanism of action through muscle biopsies among participants showed a two-fold increase in the mTOR protein and the insulin growth factor 1 (IGF-1), which are both central to muscle protein synthesis, muscle fiber regeneration and, ultimately to strength and performance.
Lonza is an integrated solutions provider that creates value along the Healthcare Continuum . Through our Pharma Biotech & Nutrition segment and our Specialty Ingredients segment businesses, we harness science and technology to serve markets along this continuum. We focus on creating a healthy environment, promoting a healthier lifestyle and preventing illness through consumers' preventive healthcare, as well as improving patient healthcare by supporting our customers to deliver innovative medicines that help treat or even cure severe diseases. Patients and consumers benefit from our ability to transfer our pharma know-how to the healthcare, hygiene and fast-moving consumer goods environment and to the preservation and protection of the world where we live.
Founded in 1897 in the Swiss Alps, Lonza today is a well-respected global company with more than 100 sites and offices and approximately 15,500 full-time employees worldwide at the end of 2018. The company generated sales of CHF 5.5 billion in 2018 with a CORE EBITDA of CHF 1.5 billion. Further information can be found at www.lonza.com.
Tel: +41 61 316 8782
Lonza Group Ltd has its headquarters in Basel, Switzerland, and is listed on the SIX Swiss Exchange. It has a secondary listing on the Singapore Exchange Securities Trading Limited ('SGX-ST'). Lonza Group Ltd is not subject to the SGX-ST's continuing listing requirements but remains subject to Rules 217 and 751 of the SGX-ST Listing Manual. Certain matters discussed in this news release may constitute forward-looking statements. These statements are based on current expectations and estimates of Lonza Group Ltd, although Lonza Group Ltd can give no assurance that these expectations and estimates will be achieved. Investors are cautioned that all forward-looking statements involve risks and uncertainty and are qualified in their entirety. The actual results may differ materially in the future from the forward-looking statements included in this news release due to various factors. Furthermore, except as otherwise required by law, Lonza Group Ltd disclaims any intention or obligation to update the statements contained in this news release.